Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:31:48.344Z.
Calculation as of: 2026-10-06T16:31:48.344Z.
Quote observation: 2026-10-06T16:30:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 719625f658538d7511a1815ebd8f3969041d2dee7d9c9a78aa46ea1e1d2f6eab
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$321.85M
EV/EBIT Ratio
34.53x
TTM Avg
44.92x
3Y Avg
44.92x
5Y Avg
44.92x
Market Cap
$308.38M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$299.52M
EV/EBIT Ratio
N/A
TTM Avg
23.87x
3Y Avg
23.87x
5Y Avg
23.87x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $324.01M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $324.71M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.85M | 34.53x | 44.92x | 44.92x | 44.92x |
| Cabaletta Bio, Inc. (CABA)vs › | $326.11M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $320.74M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $317.88M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $333.02M | 9.81x | 35.72x | 35.72x | 18.31x |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $308.38M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $299.52M | N/A | 23.87x | 23.87x | 23.87x |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $350.90M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
